Home » Posts tagged 'Shield Therapeutics plc'

Tag Archives: Shield Therapeutics plc

Ian Pollard – Stagecoach #SGC regional mileage down but fare revenue up

Stagecoach Group plc SGC updates for the year to the 27th April that it has seen further strong trading  in its UK Rail Division, resulting in an increase in expectations for adjusted earnings per share from when interim results were announced in December. The financial performance of UK rail and Virgin rail is ahead of expectations, Regional bus saw a fall of 0.5% in like for like vehicle miles but strangely like-for-like revenue per vehicle mile grew 4.0% and like-for-like revenue per journey also increased 3.6%. which seems to indicate something about fares.

Shield Therapeutics plc STX saw revenue for the year to 31st December grow from £0.6 to £11.9m whilst the annual loss fell from £19.6 million to £19.6 million1.8m. The CEO states that they are now well positioned to deliver further positive news through 2019. A significant highlight for the year was the receipt of £11.0 million upfront  from Norgine in respect of a licence agreement.

Gattaca plc GATC Profit before tax and basic earnings per share for the six months to the end of January each rose by 12% and underlying reported EBITDA by 14%. The interim dividend of 3% which was paid last year is, however, not being repeated this year in line with the revised dividend policy. The Board will consider dividends at the year end but this comes with a warning that if they are resumed it would only be at modest levels.

M. Winkworth plc WINK is pleased with its  results for 2018,  which it achieved in a sales market which it describes as testing. Weaker  sales were compensated for by ongoing growth in the rentals business which was very  successful and now accounts for half of Group revenues. Profit before tax improved slightly to £1.45 million from : £1.38 million in 2017 and the final dividend is to be increased from 7.25p  to 7.45p.

Audioboom Group plc BOOM  reports trading ahead of management expectations with quarterly revenue of c.US$4.6 million, up 180% to a record .US$4.6 million, The CEO is delighted with the first quarter start to 2019. and claims that “the potential is now there to deliver significant shareholder value this year”. with key developments including an enhanced global commercial agreements signed with Spotify a  strong pipeline of content acqusition and other opportunities, including 11 new shows which were signed during the first quarter.

 Find beachfront villas & houses for sale in Greece;   http://www.hiddengreece.net

Ian Pollard: Countryside Properties – Average Selling Prices Broadly Flat

Countryside Props plc CSP Total completions in the first quarter from the 1st October to the 30th December rose by 28 % and the forward order book by 78%. The strong growth in completions was driven by a sharp increase in affordable homes, up 52%  and Private Rental Sector, up 66% . This was due to the acquisition of Westleigh. Broadly flat average selling prices  at £395,000  with a 1% to 2% underlying increase, is not the sort of news which the housebuilding industry, likes to hear.

Restaurant Group plc RTN opened a record number of new sites in 2018 but saw like for like sales fall by 2% and total sales rise by 1%. Since the World Cup however the Group has delivered like-for-like sales growth  and the Pubs business is continuing  consistently to trade ahead of the pub restaurant sector and the Concessions business has also traded strongly. The company describes the year as a pivotal one which is hardly matched by the sales figures..

Biome Technologies plc BIOM saw 2018 group revenues show a rise of 42% over 2017.. Over 2018, sales of the non-woven filter mesh for the US single serve coffee market increased, together with other revenues, by more than 50%, The company’s portfolio of bioplastics applications are expected to contribute substantially to sales, particularly in the latter part of 2019.particularly, something known as the rigid ring project. A much higher performing disposable cutlery is another new product expected to be successful in the US. Revenues in the RF Technologies division for the year ended 31 December 2018 provided a 75% increase on the previous year. 2019 is expected to see a gradual but substantial increase in Bioplastics revenues.

Shield Therapeutics plc STX has entered 2019 in good shape with revenues for the year to 31st December 2018 expected to to have soared to. £11.9 million from 2017’s £637,000 and including the 11m. upfront payment received from Norgine on the signing of the licence agreement. Royalty income from Norgine during 2019, is anticipated to grow steadily based on sales in the UK and Germany,

 Beachfront villas & houses for sale in Greece;   http://www.hiddengreece.net

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.